Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPEN phase 3 trial of zanubrutinib versus ibrutinib in Waldenström macroglobulinemia
NL-OMON53022Phase 3Completed
- Sponsor
- BeiGene
- Start
- May 2017
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zanubrutinib and ibrutinib in Waldenström macroglobulinemia (WM) and Lymphoplasmacytic Lymphoma (LPL) (3 arms), sponsored by BeiGene. Primary endpoint: CR or VGPR rate by IRC. Started May 2017; status: completed.
02
Drugs
zanubrutinibibrutinib
03
Conditions
Waldenström macroglobulinemia (WM)Lymphoplasmacytic Lymphoma (LPL)
Beyond the preview
Go deeper on NL-OMON53022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53022.